Saliva-based RT-PCR Test
Premier Diagnostics uses a saliva-based RT-PCR test to detect the COVID-19 virus. To take this test, patients excrete saliva into a sterile test tube provided to them at the testing site. The saliva samples are then collected and transported to a processing lab located in South Jordan, Utah. There, the samples undergo a DNA amplification process called Polymerase chain reaction, or PCR. This process amplifies the possibly infected DNA to allow detection of the COVID-19 virus.
PCR tests are 98.9% accurate and have EUA approval from the FDA. Please view this summary from the FDA on diagnostic testing.
Same-day results are available to patients who test in the following locations before the designated cutoff time:
South Jordan location before 10:30 am
Daybreak locaiton before 10:30 am
Sandy locaiton before 10:30 am
West Jordan location before 10:30 am
Lehi location before 10:30 am
Pleasant Grove location before 10:30 am
Orem location before 10:15 am
Same-day test results are emailed to the patient by 8:30 pm on the day of their test. Otherwise, results are emailed to the patient by 8:30 pm the following day.
In most cases, insurance or government programs will cover 100% of the cost of your PCR saliva test. Please complete our online forms to determine if you qualify for insurance/government billing.
Disclaimer: This product has not been cleared or approved by the US Food and Drug Administration, but has been authorized by the US Food and Drug Administration under an EUA as a laboratory developed test for use by the Sports Drug Testing Laboratory. The Sports Drug Testing Laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity molecular-based clinical laboratory testing. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.